• Small Molecules
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Testimonials

We definitely consider SynVent team as a partner of choice offering scientific excellence in drug discovery, a true project team spirit and excellent project management to coordinate teams combined with a very high productivity level at the bench. 

At Qubit Pharmaceuticals, we have been delighted to partner with Syngene Integrated Drug Discovery (IDD) team on a hit to lead project aiming at developing new anti-cancer therapy.

Thanks to Syngene integrated approach we have worked in a fully collaborative and project driven way to (i) implement an appropriate flow chart for hit characterization and optimization (ii) deliver optimized hits from different chemical series. Assay development for the target of interest was very challenging and we have benefited from the high scientific expertise and proactivity of Syngene biology team to identify the most relevant assays (biochemical, biophysical and cellular). The quality of the chemistry team has been outstanding as well in term of productivity and problem solving as in terms of structure-activity-relationship (SAR) analysis and new designs proposals which were filtered using Qubit unique technology to prioritize the next compound to synthesize. We have also greatly appreciated the high flexibility of the team when we had to change priorities, which is not always the case when we use pure fee for service offers. The great advantage of the IDD format is that we have been able to work as a true project team with very good and seamless communication combined with very efficient coordination to accelerate significantly the project progression. Finally, this first phase of the collaboration has been very successful with the identification of 4 different chemical series with low nanomolar activity and preliminary ADMET data which will be used to implement the next lead optimization step. 

We are looking forward to starting the second phase of this project with Syngene IDD team and delivering optimized leads in the coming months.  

Dr. Robert Marino

CEO, Qubit Pharmaceuticals

Multiple lead compounds and discovery efforts born out of collaborative research

With my association with Syngene beginning in 2007, continuing to the present, covering multiple disciplines, including leading 600~ Syngene employees, I feel I’m very well qualified to speak to the merits of this sterling organization.

I’ve witnessed multiple lead compounds and discovery efforts born out of collaborative research between Bangalore and the US, culminating in over 20 drug candidates across various therapeutic areas. This includes refined CMC processes furnished with translational medicine from locally generated Phase 0 patient data and covering a broad range of drug platforms across small molecules and biologics. Within the context of this work, I’ve observed the entire continuum of ground-breaking research, novel ideas brought to fruition, talented individuals growing into brilliant scientists, a willingness to get things done, and a sense of urgency from the lab through to management -- all collectively rendering Syngene an ideal partner for modest biotech to large pharma.

Currently, we are deeply engaged with the SynVent* team in five unique neuroscience programs from early to late discovery.

*SynVent is Syngene’s proprietary integrated drug discovery platform.
Dr. Bruce D. Car
Chief Scientific Officer, Biohaven

Scientific discussions, flexibility and transparency, key to making our collaboration successful

We value our strong relationship with Syngene to support C4 Therapeutics’ research efforts across chemistry and biology to advance targeted protein degradation science. The scientific discussions, flexibility, and transparency between the teams have been key to making our collaboration successful.
Chris Nasveschuk
Senior Vice President, Chemistry, C4 Therapeutics

We look forward to continued successes from this collaboration

Over the past 25 years, we’ve seen a strong foundational partnership with Syngene flourish into a tremendous opportunity to expand our global R&D efforts in India, as the country provides a significant number of highly skilled and specialized talent in key areas of focus for Bristol Myers Squibb. We look forward to continued successes from this collaboration as we expand our local research and development engine.
Michael Ellis
Senior Vice President, Head, Small Molecule Drug Discovery, Bristol Myers Squibb

Syngene scientists named as inventors of this new production method

Syngene streamlined the production process of Panbela’s pancreatic cancer drug, SBP-101 while ensuring high chiral purity of 98% during GMP manufacturing. In recognition of the successful development of SBP-101 short synthesis by Syngene scientists, Panbela filed a US patent application naming Syngene scientists as the inventors of this new production method for SBP-101. This project undoubtedly brings to the fore, Syngene’s expertise and dedication in production processes for our investigational new product.

To know more about the work we did for Panbela, read Case Study
Thomas X. Neenan PhD
Chief Scientific Officer, Panbela Therapeutics Inc.

Pleased with the success of our long-standing collaboration

Amgen is pleased with the success of our long-standing collaboration with Syngene that has contributed to the advancement of a number of molecules into clinical trials. We look forward to continuing to work together with the shared goal of addressing serious disease for patients in need.

To know more about our collaboration with Amgen, read Press Release
Margret Chu-Moyer, Ph.D
Vice President of Research and Head of Chemistry, Characterization & Technology, Amgen

Congratulations for a successful partnership

As we celebrate LUMAKRAS’ Prix Galien, I want to congratulate the Syngene Amgen Research Center (SARC) and Syngene for their partnership in developing this product through a number of compounds, impurities, standards, peak markers, starting material, and advanced intermediates.
Athimoolam Arunachalampillai
Amgen Leader for SARC -Process Development

Outstanding quality of work, excellent professionalism, dedication

As a pioneer in stem cell research and treatment in Malaysia, Cytopeutics Sdn. Bhd. has worked extensively with Syngene on multiple preclinical projects such as safety (toxicity and tumorigenicity) and proof-of-concept studies for our new investigational product. We were consistently impressed with how efficiently the studies were initiated and progressed, within the stipulated timeline, despite the incredibly tight schedule and budget. We are extremely pleased with Syngene’s outstanding quality of work, excellent professionalism, and the high level of dedication of each team member to our studies. With Syngene’s help, we could complete our preclinical studies in time to support our clinical trials and product registration requirements. We look forward to working together again.

To know more about the work we did for Cytopeutics, read Case Study
Dr. Chin Sze Piaw
Clinical and Research Advisor, Cytopeutics Sdn. Bhd., Malaysia

Thank you, and congratulations, Syngene

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for our human insulin. Thank you, and congratulations to the entire Syngene team for this successful application with European Medicines Agency (EMA).
Beena Uchil, Ph.D
Director, Product Development, Capstone Development Services Co, LLC

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details